CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS FOR ICU ADMISSION OF PATIENTS WITH COVID-19 USING MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING

Jose L. Izquierdo[1,2], Julio Ancochea[3,4,5], Savana COVID-19 Research Group*, and Joan B. Soriano [3,4,5] (ORCID 0000-0001-9740-2994)

[1] Universidad de Alcalá, Madrid
[2] Hospital Universitario de Guadalajara, Guadalajara
[3] Hospital Universitario de La Princesa, Madrid
[4] Universidad Autónoma de Madrid, Madrid
[5] Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid; all in Spain

*Savana COVID-19 Research Group are: Ignacio H. Medrano, MD; Jorge Tello; Alberto Porras, MD, PhD; Marisa Serrano, PhD; Sara Lumbreras, PhD, Universidad Pontificia Comillas (ORCID: 0000-0002-5506-9027); Carlos Del Rio-Bermudez, PhD (ORCID: 0000-0002-1036-1673); Stephanie Marchesseau, PhD; Ignacio Salcedo; Andrea Martínez; Claudia Maté, MD; Sergio Collazo, MD; Jesús Barea, MD; María Villamayor, MD; Antonio Urda, MD, PhD; Carolina de la Pinta, MD; Imanol Zubizarreta; Yolanda González, PhD; Sebastian Menke, PhD (ORCID: 0000-0002-2588-6405).

Address for correspondence:
Dr. Joan B Soriano, MD, PhD, FERS, FCCP
Servicio de Neumología
Hospital Universitario de la Princesa, UAM
Diego de León 62, 28005-Madrid, Spain

Email: jbsoriano2@gmail.com
Cellular: +34 618867769

Date: May 5, 2020
File name: BigCOVIData paper_MedRxiv.docx
Word count: 3,334 words
Number of references: 36 references
Number of illustrations: 4 figures and 2 tables; Supplementary Materials: 1 figure and 1 table
Running Title: Big data and COVID-19
Conflict of Interest: Individual forms from all co-authors are appended
Keywords: artificial Intelligence, big data, COVID-19, electronic health records, tachypnoea, SARS-CoV-2

ABSTRACT

There remain many unknowns regarding the onset and clinical course of the ongoing COVID-19 pandemic. We used a combination of classic epidemiological methods, natural language processing (NLP), and machine learning (for predictive modeling), to analyse the electronic health records (EHRs) of patients with COVID-19.

We explored the unstructured free text in the EHRs within the SESCAM Healthcare Network (Castilla La-Mancha, Spain) from the entire population with available EHRs (1,364,924 patients) from January 1st to March 29th, 2020. We extracted related clinical information upon diagnosis, progression and outcome for all COVID-19 cases, focusing in those requiring ICU admission.

A total of 10,504 patients with a clinical or PCR-confirmed diagnosis of COVID-19 were identified, 52.5% males, with age of 58.2±19.7 years. Upon admission, the most common symptoms were cough, fever, and dyspnoea, but all in less than half of cases. Overall, 6% of hospitalized patients required ICU admission. Using a machine-learning, data-driven algorithm we identified that a combination of age, fever, and tachypnoea was the most parsimonious predictor of ICU admission: those younger than 56 years, without tachypnoea, and temperature <39ºC, (or >39ºC without respiratory crackles), were free of ICU admission. On the contrary, COVID-19 patients aged 40 to 79 years were likely to be admitted to the ICU if they had tachypnoea and delayed their visit to the ER after being seen in primary care.

Our results show that a combination of easily obtainable clinical variables (age, fever, and tachypnoea with/without respiratory crackles) predicts which COVID-19 patients require ICU admission.

Abstract word count: 249 words

Funding: This study was sponsored by SAVANA (https://www.savanamed.com/)

INTRODUCTION

The unprecedented, global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) requires innovative approaches that deliver immediate, real-time results[1, 2]. To date, big data technologies have only been used to estimate SARS-CoV-2 transmission[3], and to indirectly estimate COVID-19 cases in China by using social media[4]. However, there remain many unknowns regarding the onset and temporal distribution of the ongoing COVID-19 pandemic. Similarly, both the individual and population burden of COVID-19 are just beginning to be unravelled. To the best of our knowledge, such tools[5-7] have not been used to explore the clinical characteristics and prognostic factors of COVID-19[8].

Considering the unprecedented spread and severity of the ongoing COVID-19 outbreak, focus has been set on hospital's unmet need, and in particular ICU requirements[8, 9]. Indeed, health systems have been/are near collapse and independent modelling efforts have aimed to forecast a number of epidemiological estimators, including ICU use [10-12].

Previously, our team reported that the combination of big data analytics and machine learning techniques helped to better determine quality of diagnosis and treatment of chronic obstructive pulmonary disease (COPD) via an analysis of hospital electronic health records (EHRs) using natural language processing (NLP) and validated algorithms[13, 14].

By means of The BigCOVIData study, we aimed to better determine the real-world epidemiology of COVID-19 infection in a well-defined population. Using a combination of classic epidemiological methods[15], NLP, and machine learning (for predictive modeling), we analysed the clinical information contained in the EHRs of patients with COVID-19 to advance our understanding of the disease and its associated outcomes, most notably ICU admission.

METHODS

The BigCOVIData study was conducted in compliance with legal and regulatory requirements and followed generally accepted research practices described in the ICH Guideline for Good Clinical Practice, the Helsinki Declaration in its latest edition, Good Pharmacoepidemiology Practices, and applicable local regulations. This study was classified as a 'non-post-authorization study' (EPA) by the Spanish Agency of Medicines and Health Products (AEMPS), and it was approved by the Research Ethics Committee at the University Hospital of Guadalajara (Spain). We have followed and endorsed the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidance for reporting observational research[16].

Study design and data source

This was a multicenter, non-interventional, retrospective study using data captured in the EHRs of the participating hospitals within the SESCAM Healthcare Network in Castilla-La Mancha, Spain (**Figure 1**). Data captured in the EHRs was collected from all available departments, including inpatient hospital, outpatient hospital, and ER, for virtually all types of provided services in each participating hospital. The study period was January 1, 2020 – March 29, 2020.

The study database was fully anonymized in a structured format and contained no
personal information from patients. Likewise, personal information was not accessed
during either the application of automated and algorithmic methods (i.e., NLP) or during
the conversion of unstructured data into the structured database. Importantly, given that
clinical information was handled in an aggregate, anonymized, and irreversibly
dissociated manner, patient consent regulations do not apply to the present study

Study sample

The study sample included all patients in the source population diagnosed with COVID-
19. Patients were identified on the basis of clinical diagnosis (i.e., COVID-19 cases
determined by observed symptomatology, imaging (mostly chest X-ray) and laboratory
results, as captured in the unstructured, free-text information in the EHRs) and/or
microbiological test results (i.e., COVID-19 cases confirmed by RT-PCR or similar
available tests). Our decision to consider both PCR- and clinically confirmed cases is
justified by the limited availability of routinely administered RT-PCR tests in the region
during the study period and supported by recent discussions on the far-from-optimal
sensitivity of RT-PCR for COVID19 (i.e., a single negative result from a single specimen
cannot exclude the disease in suspected cases)[17, 18]. Indeed, recent reports highlight
the clinical validity and relatively high sensitivity of symptom- and imaging-based
identification of COVID-19 patients, especially in early stages of the disease[17, 19, 20].

EHRead®

To meet the study objectives, we used *EHRead*®[21], a technology developed by
SAVANA that applies NLP, machine learning, and deep learning to analyse the
unstructured free-text information written in millions of de-identified EHRs. This
technology enables the extraction of information from all types of EHRs and the
subsequent normalization of extracted clinical entities to a unique terminology. This
process allows for further analysis of descriptive or predictive nature. Originally based
on SNOMED CT terminology, our unique body of terminology comprises more than
400,000 medical concepts, acronyms, and laboratory parameters aggregated over the
course of five years of free-text mining, targeting the most common diseases (e.g.
respiratory diseases, cardiovascular diseases, and diabetes, among others).

Using a combination of regular expression (regex) rules and machine learning models,
the terminology entities are detected in the unstructured text and later classified based
on sections typically contained in the EHRs, hospital services, and other clinical
specifications. Importantly, each detected term is described in terms of negative,
speculative, or affirmative clinical statements; this is achieved by using deep learning
CNN classification methods that rely on word embeddings and context information (for a
similar methodological approach, see [22]). Limitations in a case by case detection are
also overcome with a similar approach to ensure that the detected concepts are used
within the appropriate context for the descriptive and predictive analysis.

For particular cases where extra specifications are required (i.e., to differentiate COVID
cases from other mentions of the term related to fear of the disease or to potential
contact), the detection output was manually reviewed in more than 5000 reports to avoid
any possible ambiguity associated with free-text reporting. All NLP deep learning models
used in this study were validated using the standard training/validation/testing approach;
we used a 75/12/13 split ratio in the available annotated data (between 2,000 and 3,000
records, depending on the model) to ensure efficient generalization on unseen cases.
For all developed models, we obtained F-scores greater than 0.89.

Data Analyses

All categorical variables (e.g., comorbidities, symptoms) are shown in frequency tables,
whereas continuous variables (e.g., age) are described via summary tables that include
the mean, standard deviation, median, minimum, maximum, and quartiles of each
variable. The number of missing data points for each variable is provided, if any. To test
for possible statistically significant differences in the distribution of categorical variables
between study groups (i.e., male vs. female, ICU admission vs. No ICU admission), we
used Yates-corrected chi^2 tests. For continuous variables, mean differences were tested
using t-tests. Given our general population approach, and our larger than usual sample
size, we were interested in exploring sex-related differences in COVID-19 patients, so
most results are stratified by sex[23]. All statistical inferences were performed at the 5%
significance level using 2-sided tests or 2-sided CIs.

Predictive model

We developed a decision tree to classify COVID-19 patients according to their risk of
being admitted to the ICU. The two types of patients or *classes* considered in the model
were therefore "admitted to the ICU" and "not admitted to the ICU". The model maps the
characteristics of patients (the *variables*) to their class in the shape of a tree. From a
clinical perspective, this model contemplates all patient variables upon admission,
meaning that its predictive value is so from symptom debut until outcome. The tree is
composed of nodes that branch to subsequent children nodes depending on the patient's
variables. The tree is built in such a way that each branch separates the two classes as
much as possible. This separation is measured as *Shannon entropy*, where a node with
an entropy of zero means that the classification is perfect (either all or none of the
patients were admitted to the ICU) and an entropy of one is the worst possible mix
(50%/50%)[24].

Model training and validation. The model was developed and tested on the available data
from hospitalized patients that had either been admitted to the ICU or not; the latter were
either discharged from the hospital or died in the course of the disease. This amounted
to a total of 900 patients. Our algorithm was validated in a split of our COVID-19 sample,
in a 70% training set and a 30% validation set. This means that the model was trained
with 630 patients (582 who did not require intensive care, vs 48 who did) and validated
over the remaining 270 patients. Because the two classes were unbalanced (far fewer
patients require ICU), we used the standard technique of oversampling the lower class
to guarantee a balance of accuracy and recall (in other words, the tradeoff between false
positives vs. false negatives). Further, we sought to replicate the results from this
validation in *a posteriori* sensitivity analysis, as per recent recommendations for
predictive modeling in COVID-19[25] and TRIPOD guidance[26]. For this second
validation, we trained the model with data from the provinces of Ciudad Real and
Guadalajara (38% of the study sample from Castilla La-Mancha), and used an
independent set with combined data set from the other three provinces, namely Toledo,
Cuenca, and Albacete for validation.

RESULTS
212
From a source general population of 2,035,000 inhabitants, we used NLP and machine
learning to analyse the clinical information contained in the EHRs of 1,364,924
anonymous patients (**Figure 1**). Among these, we identified a total of 10,504 patients

diagnosed with COVID-19 (**Figure 2**). The flowchart of participation in the study up to
hospital admission, ICU admission, or discharge is presented in **Figure 2**.

COVID-19 patients were 52.5% males, with a mean±SD age of 58.2±19.7 years, (**Table
1**). Most COVID-19 patients were 50 years and older **(Figure 3)**. Upon diagnosis, the
most common symptoms reported were cough, fever and dyspnoea (**Table 1**); notably,
less than half of patients presented with these symptoms, probably due to the fact that
most were attended in primary care. Further, respiratory crackles, myalgia, and diarrhoea
were identified in 5% or more of cases, while other respiratory and non-respiratory signs
and symptoms were less common. Sex-dependent differences in sign and symptom
frequencies upon diagnosis are shown in **Table 1**. Of note, we observed subtle increases
in frequency of diarrhoea, myalgia, headache, chest pain, and anosmia in female
COVID-19 patients, while men showed significant increases in fever, dyspnoea,
respiratory crackles, ronchus, lymphopenia, and tachypnoea (all p<0.05).

Similarly, the most frequent comorbidities were cardiovascular disease (48.2% of
patients) -mainly arterial hypertension (33.6%) and heart disease (25.1%)- and diabetes
(15.7%) (**Table 1**). Regarding respiratory diseases, COPD was present in 6.4%, asthma
in 7.2%, OSA in 2%, and bronchiectasis in 1.2% of patients. Sex-dependent differences
in comorbidities upon diagnosis are also shown in **Table 1**; except for asthma, the
frequency of all comorbidities was significantly higher in male than female COVID-19
patients (all p<0.05).

Next, we explored whether the distribution of comorbidities and sign/symptoms captured
in the patients' EHRs upon diagnosis differed between those COVID-19 patients who
were admitted to the ICU vs. those who were not (**Table 2**). Regarding comorbidities,
diabetes, obesity, cardiovascular disease (mainly hypertension), heart disease (mainly
ischemic heart disease), and renal dysfunction were more common among those
patients who were admitted to the ICU (all p < 0.01). As for signs and symptoms, cough,
fever, dyspnoea, respiratory crackles, diarrhoea, tachypnoea, lymphopenia, and
rhonchus were more frequent among ICU patients (all p < 0.05). Interestingly, respiratory
diseases were not more frequent among patients who were admitted to the ICU (**Table
2**).

Finally, by using a machine-learning, data-driven algorithm, we identified that the
combination of three easily available clinical variables, namely age, temperature, and
respiratory frequency, was the most parsimonious predictor of ICU admission among
COVID-19 patients (**Figure 4**). For this model, age and temperature were captured as
continuous variables, whereas tachypnoea (yes/no) was defined as respiratory
frequency of more than 20 breaths per minute. With accuracy, recall, and AUC values of
0.68, 0.71, and 0.76, respectively, the presented model reached optimal balance in terms
of positive and negative predictive value for ICU admission. On the one hand, those
younger than 56 years, without tachypnoea, and with temperature <39ºC/102ºF (entropy
= 0, n = 145) (or >39ºC/102ºF without respiratory crackles), were free of ICU admission,
(entropy = 0, n = 18). On the other hand, COVID-19 patients aged 40 to 70 years were
likely to be admitted in the ICU if they presented with tachypnoea and delayed their visit
to the ER after being seen in primary care (entropy = 0, n = 104). As stated in the Methods
section, we performed an additional sensitivity analysis with different data sets to further
validate the results of our predictive model. The independent data set of two provinces
(Ciudad Real and Guadalajara, including a total of 753,408 individual patients, or 38%
of the entire study sample from Castilla-La Mancha; **Figure 1** and **Supplemental Table
S1**), was used to retrain our algorithm to identify ICU admission at onset; validation was
performed in the remaining three provinces. As shown in **Supplemental Figure S1**, the

new decision tree identified the same relevant clinical variables, that is age, tachypnea,
temperature, and respiratory crackles/ronchus with similar (but not identical) thresholds
in some of them. This additional model reached values of accuracy, recall, and AUC of
0.85, 0.57, and 0.84, respectively, thus providing additional proof of validity for our main
findings.

DISCUSSION

Recent technological advances allow for the optimal and rapid extraction, integration,
and analysis of the unique and massive amount of untapped medical knowledge
captured in the EHRs. This possibility is particularly meaningful when the clinical
question at hand requires collecting data from a large number of patients in a very limited
amount of time, as is the case with the newly described COVID-19 pandemic.

By anonymously accessing the clinical information of more than 10,000 anonymous
patients with COVID-19 (a number that largely surpasses samples included in recent
reports about the disease[27, 28]), we were able to describe their demographic and
clinical characteristics, their clinical journey, and the statistical relationship between the
most common symptoms and comorbidities on admission, and COVID-19 prognosis (i.e.,
ICU admission). There were subtle differences in clinical symptoms at onset by sex,
while all comorbidities (but asthma) were significantly higher in male than female COVID-
19 patients; these and other findings should be replicated in clinical series elsewhere.

The variables identified in our ICU admission model (i.e., age, temperature, and
tachypnoea) are clinically relevant as they are readily available and easily observable in
the everyday practice with COVID-19 patients. Although tachypnea is not an exclusive
manifestation of COVID-19 and can be present in patients suffering from other
respiratory diseases (i.e., pneumonia), our model suggests that this sign (in combination
with age and temperature) is the most reliable predictor of ICU use over other common
symptoms and signs such as cough, dyspnea, or respiratory crackles.
292
293 In addition, given that the stability and capacity of ICUs worldwide is threatened by the
294 rapid spread of the disease, the identification of individual factors that predict ICU
295 admission may not only improve patient management but also optimize healthcare
296 resource use and planning.
297
Further applied to other national and international healthcare networks, the tools and
methodology presented here can potentially characterize and predict the prognosis of
COVID-19 in a timely and unprecedented manner. As recently pointed out[29, 30], there
might be value in the application of artificial intelligence to the current COVID-19
pandemic, not only to predict outbreaks[31] or read chest CT scans[32], but also to
disentangle COVID-19's clinical onset and natural history in nearly real-time. Indeed,
classical methods would have required months of questionnaire-based data collection
and questionnaire validation, along with multiple Ethics Board approvals and other
practical hurdles, all saved with our current approach.
307
308 In the race against COVID-19[33], where the goal is to curb the pandemic, it is imperative
309 to leverage big data and intelligent analytics for the betterment of public health. However,
310 it is of the utmost importance not to neglect privacy and public trust, to keep best
311 practices, and to maintain responsible standards for data collection and data processing
312 at a global scale[34].

Strengths and Limitations

To our knowledge, this is the first study using NLP and machine learning to access real-world data in such a large COVID-19 population. Indeed, our state-ot-the-art methodology allowed for the rapid analysis of the unstructured free-text narratives in the EHRs of one million patients from the general population of the region of Castilla La-Mancha (Spain).

Our methodology combined modules for sentence segmentation, tokenization, text normalization, acronym disambiguation, negation detection, and a multi-dimensional ranking scheme; the latter involved linguistic knowledge, statistical evidence, and continuous vector representations of words and documents learned via shallow neural networks. When applied to EHRs, NLP enables *a)* access to entire track records for *all* patients in the target population, and *b)* the implementation of exploratory analysis to unravel associations between variables that have remained undetected with traditional research methods. By considering all possible patients with the target disease, the information and analyses used here (i.e., RWD and free-scale statistics) remained unbiased by the research question or the observers. Unlike classical statistical methods (e.g., logistic regression), the main advantage associated with the use of ML in this context is that it allows for the automatic detection of meaningful relationships between variables. For instance, if a given symptom (i.e., fever) is only relevant for certain patients (i.e., older than 50), techniques such as the classification trees used here are suitable to uncover this relationship. In this context, although the total number of patients that required ICU use in the training set was somewhat low (48 patients), the number of variables considered in the model was also very limited. In addition, the inclusion of a validation stage reduces the likelihood of overfitting. Ultimately, the use of classifications trees in this study (as opposed to other models such as Artificial Neural Networks) is especially appropriate in the clinical context because they are easily interpretable.

Regarding the geographical location of our participating hospital sites, it is worth mentioning that with a total of 1,364,924 patients from the region of Castilla La-Mancha (SESCAM Healthcare Network), our sample is representative of the Spanish population; Spain has been among the hardest hit countries by the pandemic, in terms of both total cases and mortality rates [35, 36], and this region in particular is the third most affected in the country, just behind Madrid and Catalonia. For this reason, we anticipate that the clinical conclusions drawn here are relevant for clinicians worldwide. Of note, ICU capacity in the region during the study period was not compromised yet, which protects against possible bias in our training data (all patients requiring intensive care were indeed admitted to the ICU).

The results and conclusions of the present study should be interpreted in light of the following limitations. First, we did not distinguish COVID-19 cases confirmed by laboratory results (i.e, RT-PCR) from those exclusively diagnosed through clinical observation (i.e., symptomatology, imaging and laboratory results). However, it should be noted that PCR and other rapid laboratory tests for the detection of SARS-CoV-2 were not routinely administered in Spain during the study period. In addition, this decision is supported by recent discussions on the clinical validity and relatively high sensitivity of symptom- and imaging-based identification of COVID-19 patients, especially in early stages of the disease[17, 19, 20]. Second, independent replications by different research groups in larger patient sets are needed to further support the clinical validity of our results.

Finally, future reports from the BIGCOVIData study may incorporate laboratory results
and treatments, and contextualize the results presented here in a larger clinical
picture[25].

We conclude that, in the largest series of COVID-19 patients attended during the first
three months of the pandemic in Spain, 6% of all hospitalized patients required ICU; and
that a combination of easily obtained clinical variables, namely age, fever, and
tachypnoea predicts which COVID-19 patients require ICU admission.

Acknowledgments. We thank all the Savaners for helping accelerate health science
with their daily work. This would have not been possible without every single team
member. We also thank SESCAM (Healthcare Network in Castilla-La Mancha, Spain)
for its participation in the study and for supporting the development of cutting-edge
technology in real time.

REFERENCES

1.   Centers for Disease Control and Prevention (CDC). Coronavirus (COVID-19) at CDC & P. Available from https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed April 8, 2020

2.   Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020: 382(8): 727-733.

3.   Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, Parker M, Bonsall D, Fraser C. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* 2020.

4.   Qin L, Sun Q, Wang Y, Wu KF, Chen M, Shia BC, Wu SY. Prediction of Number of Cases of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index. *Int J Environ Res Public Health* 2020: 17(7).

5.   Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019: 25(1): 44-56.

6.   Divita G, Carter M, Redd A, Zeng Q, Gupta K, Trautner B, Samore M, Gundlapalli A. Scaling-up NLP Pipelines to Process Large Corpora of Clinical Notes. *Methods Inf Med* 2015: 54(6): 548-552.

7.   Burgner D, Jamieson SE, Blackwell JM. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? *Lancet Infect Dis* 2006: 6(10): 653-663.

8.   Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, Wang L, Zhang L, Li QH, Zhao L, He Y, Gu XL, Ji XB, Li L, Jie ZJ, Li Q, Li XY, Lu HZ, Zhang WH, Song YL, Qu JM, Xu JF. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. *Eur Respir J* 2020.

9.   Horton R. Offline: COVID-19-what countries must do now. *The Lancet* 2020: 395(10230): 1100.

10.   Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, Cohn EL, Hswen Y, Hill SC, Cobo MM, Zarebski AE, Li S, Wu C-H, Hulland E, Morgan JD, Wang L, O'Brien K, Scarpino Samuel V, Brownstein JS, Pybus OG, Pigott DM, Kraemer MUG. Epidemiological data from the COVID-19 outbreak, real-time case information. *Scientific Data* 2020: 7(1): 106.

11.   Murray CJ. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months. *medRxiv* 2020: 2020.2003.2027.20043752.

12.   Sotgiu G GGCS, Miozzo M, Canonica GW, Virchow JC, Soriano JB. Advanced forecasting of SARS-CoV-2 related deaths in Italy, Germany and Spain. *Allergy* 2020: In Press.

13.   Izquierdo JL, Morena D, Gonzalez Y, Paredero JM, Perez B, Graziani D, Gutierrez M, Rodriguez JM. Clinical Management of COPD in a Real-World Setting. A Big Data Analysis. *Arch Bronconeumol* 2020.

14.   Sociedad Española de Neumología y Cirugía Torácica. Chart Review of Patients With COPD, Using Electronic Medical Records and Artificial Intelligence (BigCOPData). Available from https://clinicaltrials.gov/ct2/show/NCT04206098. Accessed April 13, 2020.

15.   Koo D, Thacker SB. In snow's footsteps: Commentary on shoe-leather and applied epidemiology. *Am J Epidemiol* 2010: 172(6): 737-739.

16.   STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidance for reporting observational research.Available from http://strobe-statement.org/index.php?id=strobe-home. Accessed April 13, 2020.

17.   Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol* 2020: 126: 108961.

18.   Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020.

19.   Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT
and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
Radiology: 0(0): 200642.
20.   Xu J, Wu R, Huang H, Zheng W, Ren X, Wu N, Ji B, Lv Y, Liu Y, Mi R. Computed
Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative
Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test. *Clinical Infectious
Diseases* 2020.
21.   Hernandez Medrano ITG, J; Belda, C; Urena, A; Salcedo, I; Espinosa-Anke, L; Saggion, H.
Savana: Re-using Electronic Health Records with Artificial Intelligence. *International Journal of
Interactive Multimedia and Artificial Intelligence* 2017: 4(7): 8-12.
22.   Yang Z, Dehmer M, Yli-Harja O, Emmert-Streib F. Combining deep learning with token
selection for patient phenotyping from electronic health records. *Scientific Reports* 2020:
10(1): 1432.
23.   The Lancet. The gendered dimensions of COVID-19. *The Lancet* 2020: 395(10231):
1168.
24.   Quinlan JR. Induction of decision trees. *Machine Learning* 1986: 1(1): 81-106.
25.   Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, Haller MC,
Heinze G, Moons KGM, Riley RD, Schuit E, Smits LJM, Snell KIE, Steyerberg EW, Wallisch C, van
Smeden M. Prediction models for diagnosis and prognosis of covid-19 infection: systematic
review and critical appraisal. *BMJ* 2020: 369: m1328.
26.   Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers
AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for
Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015:
162(1): W1-73.
27.   Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, Gaymard A,
Bouscambert-Duchamp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M,
Mailles A, Lucet JC, Mentre F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S,
Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case
series. *Lancet Infect Dis* 2020.
28.   Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing
X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q,
Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi
G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission
Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020:
382(13): 1199-1207.
29.   McCall B. COVID-19 and artificial intelligence: protecting health-care workers and
curbing the spread. *The Lancet Digital Health* 2020: 2(4): e166-e167.
30.   Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Guo GY, Du J, Zheng CL, Zhu Q, Hu M,
Li XY, Peng P, Shi HZ. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by
SARS-CoV-2: A Prospective Cohort Study. *Eur Respir J* 2020.
31.   Ayyoubzadeh SM, Ayyoubzadeh SM, Zahedi H, Ahmadi M, S RNK. Predicting COVID-19
Incidence Through Analysis of Google Trends Data in Iran: Data Mining and Deep Learning Pilot
Study. *JMIR Public Health Surveill* 2020: 6(2): e18828.
32.   Li L, Qin L, Xu Z, Yin Y, Wang X, Kong B, Bai J, Lu Y, Fang Z, Song Q, Cao K, Liu D, Wang
G, Xu Q, Fang X, Zhang S, Xia J, Xia J. Artificial Intelligence Distinguishes COVID-19 from
Community Acquired Pneumonia on Chest CT. *Radiology* 2020: 200905.
33.   The race against COVID-19. *Nat Nanotechnol* 2020: 15(4): 239-240.
34.   Ienca M, Vayena E. On the responsible use of digital data to tackle the COVID-19
pandemic. *Nat Med* 2020: 26(4): 463-464.
35.   World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation
Report –64. 2020. Available from https://www.who.int/docs/default-

source/coronaviruse/situation-reports/20200324-sitrep-64-covid-19.pdf?sfvrsn=723b221e_2

Accessed March 24, 2020

36.   Spanish Ministry of Health. Situación de COVID-19 en España. Ministerio de Sanidad

2020. Availabe from https://covid19.isciii.es. Accessed April 13, 2020.

FIGURES and TABLES

482 **Figure 1. Map of Castilla-La Mancha**.

483 **Footnote**: Map of Castilla-La Mancha (red) within the Spanish (blue line) and
484 European territories. From a source general population of 2,035,000 inhabitants, we
485 collected and analyzed the clinical information in the EHRs of 1,364,924 patients within
486 the SESCAM Healthcare Network.

487

488 **Figure 2. Patient flowchart.**

489 **Footnote**: Flowchart depicting the total number of inhabitants in the source population,
490 the number (%) of patients with available EHRs analyzed, the number of patients
491 diagnosed with COVID-19, and of those, the number of hospitalizations and ICU
492 admissions.

494 **Figure 3. Age and Sex Distribution of COVID-19 patients.**

495 **Footnote**: Age distribution of incident cases of COVID-19 in females (left) and males
496 (right) in the study population for the period comprised between Jan 1, 2020 and March
497 29, 2020.

Figure 4. Decision tree of relevant clinical variables for the prediction of ICU admission in COVID-19 patients.

Footnote: The combination of three easily available clinical variables, namely age, temperature, and respiratory frequency, was the most parsimonious predictor of ICU admission among COVID-19 patients. The number of patients, probability (p) of ICU admission predicted by the model, and level of entropy (a measure indicating how mixed or pure the classification is, where 0 indicates optimal separation of classes) are indicated in each box. The green pathway indicates that those patients with no tachypnoea, younger than 56 years old, and with temperature less than 39ºC/102ºF (OR more than 39ºC/102ºF without respiratory crackles), did not require ICU admission. On the contrary, the red pathway indicates that patients aged 40-79 years, who presented with tachypnoea, and delayed their visit to the ER after being seen in primary care, were likely to be admitted in the ICU. For this model, we obtained accuracy, recall, and AUC values of 0.68, 0.71, and 0.76, respectively (top right panel). See text for further details.

513 **TABLE 1. Baseline demographics and clinical data upon diagnosis.**

	Female n = 4,984	Male n = 5,519	TOTAL n = 10,504	p-value*
Sex				
Female			4,984(47.4)	
Male			5,519(52.5)	
Unknown			1(0.0)	
Age (in years)				
Mean(SD)	57.4(20.0)	59.0(19.5)	58.2(19.7)	<0.001
Median(Min-Max)	58.0(0.0-100.0)	60.0(0.0-102.0)	59.0(0.0-102.0)	
(Q1-Q3)	(44.0-73.0)	(46.0-74.0)	(45.0-73.0)	
Signs and Symptoms n(%)				
Cough	2,482(49.8)	2,760(50.0)	5,243(49.9)	0.8453
Fever	2,120(42.5)	2,783(50.4)	4,904(46.7)	<0.001
Dyspnoea	1,476(29.6)	1,818(32.9)	3,294(31.4)	<0.001
Respiratory crackles	849(17.0)	1,085(19.7)	1,934(18.4)	<0.001
Diarrhoea	556(11.2)	543(9.8)	1,099(10.5)	0.03
Myalgia	467(9.4)	451(8.2)	919(8.7)	0.0326
Headache	462(9.3)	302(5.5)	764(7.3)	<0.001
Rhonchus	279(5.6)	414(7.5)	693(6.6)	<0.001
Chest pain	287(5.8)	267(4.8)	554(5.3)	0.039
Lymphopenia	196(3.9)	346(6.3)	542(5.2)	<0.001
Wheezing	194(3.9)	195(3.5)	389(3.7)	0.3567
Tachypnoea	135(2.7)	203(3.7)	338(3.2)	0.0059
Anosmia	166(3.3)	134(2.4)	300(2.9)	0.0066
Sore throat	69(1.4)	57(1.0)	127(1.2)	0.118
Ageusia	33(0.7)	32(0.6)	65(0.6)	0.68
Dysphagia	19(0.4)	28(0.5)	47(0.4)	0.4119
Neuralgia	19(0.4)	22(0.4)	41(0.4)	1
Splenomegaly	8(0.2)	14(0.3)	22(0.2)	0.4071
Hepatomegaly	2(0.0)	6(0.1)	8(0.1)	0.3586
Comorbidities n(%)#				
Cardiovascular disease	2,253(45.2)	2,805(50.8)	5,058(48.2)	<0.001
Hypertension	1,552(31.1)	1,975(35.8)	3,527(33.6)	<0.001
Ischemic stroke	91(1.8)	163(3.0)	254(2.4)	<0.001
Heart Disease	1100(22.1)	1539(27.9)	2639(25.1)	<0.001
Ischemic heart disease	152(3.0)	475(8.6)	627(6.0)	<0.001
Heart failure	243(4.9)	309(5.6)	552(5.3)	0.1063
Diabetes	689(13.8)	957(17.3)	1646(15.7)	<0.001
Obesity	479(9.6)	457(8.3)	936(8.9)	0.0185
Renal dysfunction	271(5.4)	493(8.9)	764(7.3)	<0.001
CKD	171(3.4)	323(5.9)	494(4.7)	<0.001
Depression	484(9.7)	219(4.0)	703(6.7)	<0.001
Chronic respiratory disease	242(4.9)	646(11.7)	888(8.5)	<0.001
Asthma	496(10.0)	263(4.8)	759(7.2)	<0.001
COPD	126(2.5)	549(9.9)	675(6.4)	<0.001
Obstructive sleep apnea syndrome (OSA)	69(1.4)	143(2.6)	212(2.0)	<0.001
Bronchiectasis	42(0.8)	87(1.6)	129(1.2)	<0.001
Chronic Liver Disease	36(0.7)	75(1.4)	111(1.1)	0.002
Cirrhosis	16(0.3)	35(0.6)	51(0.5)	0.0304
HIV	12(0.2)	22(0.4)	34(0.3)	0.2113

Footnote: *p-values from Yates-corrected chi^2 test on percentage difference of female vs. male COVID-19 patients. All
tests were performed individually for each variable (comorbidity or sign/symptom, where applicable). For numerical values
(i.e., age), t-tests of difference between means were used. #List of medical conditions according to SNOMED CT
terminology.

TABLE 2. Association between ICU admission and comorbidities/signs and symptoms upon
diagnosis in patients with COVID-19.

COMORBIDITIES				SIGNS AND SYMPTOMS			
Condition[#]	No ICU n(%)	ICU n(%)	p-value*	Sign or Symptom	No ICU n(%)	ICU n(%)	p-value*
Diabetes	1613(15.5)	33(39.8)	<0.001	Cough	5181(49.7)	62(74.7)	<0.001
Obesity	917(8.8)	19(22.9)	<0.001	Fever	4849(46.5)	55(66.3)	<0.001
Chronic respiratory disease	883(8.5)	5(6)	0.548	Dyspnoea	3246(31.1)	48(57.8)	<0.001
COPD	673(6.5)	2(2.4)	0.2029	Respiratory crackles	1904(18.3)	30(36.1)	<0.001
Asthma	750(7.2)	9(10.8)	0.2868	Myalgia	908(8.7)	11(13.3)	0.2066
OSA	211(2)	1(1.2)	0.8908	Diarrhoea	1084(10.4)	15(18.1)	0.0363
Bronchiectasis	129(1.2)	0(0)	0.6033	Dysphagia	47(0.5)	0(0)	1
Cardiovascular disease	4998(48)	60(72.3)	<0.001	Wheezing	383(3.7)	6(7.2)	0.1568
Hypertension	3487(33.5)	40(48.2)	0.0066	Tachypnoea	311(3)	27(32.5)	<0.001
Ischemic stroke	253(2.4)	1(1.2)	0.716	Chest pain	546(5.2)	8(9.6)	0.1237
Heart Disease	2604(25)	35(42.2)	<0.001	Lymphopenia	524(5)	18(21.7)	<0.001
Ischemic Heart Disease	616(5.9)	11(13.3)	0.0099	Headache	757(7.3)	7(8.4)	0.8442
Heart failure	548(5.3)	4(4.8)	1	Rhonchus	676(6.5)	17(20.5)	<0.001
Renal dysfunction	748(7.2)	16(19.3)	<0.001	Hepatomegaly	8(0.1)	0(0)	1
CKD	488(4.7)	6(7.2)	0.4059	Anosmia	297(2.9)	3(3.6)	0.9317
Chronic Liver Disease	109(1)	2(2.4)	0.502	Ageusia	65(0.6)	0(0)	0.9847
Cirrhosis	51(0.5)	0(0)	1	Neuralgia	41(0.4)	0(0)	1
Depression	699(6.7)	4(4.8)	0.6418	Sore throat	126(1.2)	1(1.2)	1
HIV	33(0.3)	1(1.2)	0.6536	Splenomegaly	21(0.2)	1(1.2)	0.4317

521 **Footnote**: *p-values from Yates-corrected chi^2 test of difference between percentage of patients in either outcome group.
522 All tests were performed individually for each variable (comorbidity or sign/symptom, where applicable). [#]List of medical
523 conditions according to SNOMED CT terminology.